PO.CL12.04 · 临床研究
68Ga-DOTANOC PET/CT与解剖成像在儿童斜视性眼阵挛-肌阵挛-共济失调综合征中的比较:一项回顾性分析
Comparison of 68 Ga-DOTANOC PET/CT with anatomical imaging in opsoclonus-myoclonus-ataxia syndrome in children: A retrospective analysis
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
引言:斜视性眼阵挛-肌阵挛-共济失调综合征(OMAS),又称"Kinsbourne综合征"或"舞动眼综合征",是一种罕见的免疫介导的副肿瘤性神经综合征,约2-3%的1-3岁儿童可能与小儿神经母细胞瘤相关。OMAS预后不良,其特征为不自主的眼球运动、肌肉抽动、共济失调和行为改变。在多达50%的儿童中,小儿神经母细胞瘤可能是OMAS的唯一病因。检测隐匿性神经母细胞瘤的常规检查包括用USG/CT/MRI对胸部和腹部进行解剖成像。131I-MIBG闪烁显像也被使用;然而,其应用因可获得性、需要繁琐的患者准备以及高辐射暴露而受限。在本回顾性分析中,我们评估了接受68Ga-DOTANOC PET/CT作为单一筛查检查以检测神经母细胞瘤并对疾病进行分期的OMAS患儿,并与传统解剖成像进行比较。
方法:评估了2019年1月至2024年6月期间43例表现为OMAS的儿科患者的68Ga-DOTANOC PET/CT扫描回顾性数据。CT图像上存在相应形态学改变且表达生长抑素受体(SSTR)的病灶被视为PET阳性,而无异常SSTR表达或病灶则被视为PET阴性。68Ga-DOTANOC PET/CT的结果还与既往解剖成像检查进行了比较,32例患者可获得既往成像(PET阳性和PET阴性两组均有)。
结果:43例患者(21名男性,22名女性;平均年龄1.5岁)中,31例(72.1%)为PET阳性,12例(27.9%)为PET阴性。PET阳性病灶的平均SUVmax为12.1(SD = 6.6)。32例患者可获得既往解剖成像检查(USG(n=13)/CT(n=6)/MRI(n=13)),并与68Ga-DOTANOC PET/CT进行比较。5例既往USG患者和1例既往MRI患者出现不一致,其中3例患者在USG上遗漏病灶、1例患者在MRI上遗漏病灶。1例患者中,1个可疑病灶被68Ga-DOTANOC PET/CT排除诊断。根据国际神经母细胞瘤分期系统(INSS),24例(80%)为1期,4例(6.4%)为2期,1例(4%)为3期,2例(6.4%)为4期。7/31例1期患者在手术切除后进行了重复68Ga-DOTANOC PET/CT,均为PET阴性。
结论:在本回顾性分析中,我们发现约72%表现为OMAS的儿童以神经母细胞瘤作为主要病因。68Ga-DOTANOC PET/CT表现出高诊断性能,能够准确识别神经母细胞瘤并提供快速诊断、转移检测以及最佳管理指导。
查看英文原文 English abstract
Introduction: Opsoclonus-myoclonus-ataxia syndrome (OMAS), also known as “Kinsbourne syndrome” or “dancing eye syndrome,” is a rare immune-mediated paraneoplastic neurological syndrome that may be associated with pediatric neuroblastoma in approximately 2-3% of children aged 1-3 years. OMAS carries a grave prognosis and is characterised by involuntary eye movements, muscle jerks, ataxia and behavioural changes. Paediatric neuroblastoma may be the only cause of OMAS in up to 50% of children. Routine tests to detect occult neuroblastoma include anatomical imaging of the chest and abdomen with USG/ CT/ MRI. 131 I-MIBG scintigraphy has also been used; however, its application is limited by its availability, need for strenuous patient preparation, and high radiation exposure. In this retrospective analysis, we evaluated children presenting with OMAS who underwent 68 Ga-DOTANOC PET/CT as a single screening study to detect neuroblastoma and stage the disease, in comparison to traditional anatomical imaging.
Methods: Retrospective data from 68 Ga-DOTANOC PET/CT scans of 43 pediatric patients presenting with OMAS from January 2019 to June 2024 were evaluated. A somatostatin receptor (SSTR) expressing lesion with corresponding morphological change on the CT image was considered PET-positive, while no abnormal SSTR expression or lesion was considered PET-negative. The results of 68 Ga-DOTANOC PET/CT were also compared with prior anatomical imaging studies, which were available for 32 patients (in both PET-positive and PET-negative groups).
Results: Of 43 patients (21 male, 22 female; mean age 1.5 years), 31 (72.1%) were PET-positive and 12 (27.9%) were PET-negative. The mean SUVmax of PET-positive lesions was 12.1 (SD = 6.6). Prior anatomical imaging studies (USG (n=13)/ CT (n=6)/ MRI (n=13)) were available in 32 patients and compared with 68 Ga-DOTANOC PET/CT. Discordance was seen in 5 patients with prior USG and 1 patient with prior MRI, in which lesions were missed in 3 patients on USG and 1 patient on MRI. One suspicious lesion was excluded from diagnosis by 68 Ga-DOTANOC PET/CT in 1 patient. According to the International Neuroblastoma Staging System (INSS), 24 (80%) were stage 1, 4 (6.4%) were stage 2, 1 (4%) were stage 3, and 2 (6.4%) were stage 4. Repeat 68 Ga-DOTANOC PET/CT was done in 7/31 of stage 1 patients after surgical excision, and all were PET-negative.
Conclusion: In this retrospective analysis, we found that approximately 72% of children presenting with OMAS have neuroblastoma as the primary etiology. 68 Ga-DOTANOC PET/CT demonstrated high diagnostic performance, accurately identifying neuroblastoma and providing rapid diagnosis, detection of metastasis, and guidance for optimal management.
利益披露 Disclosure
A. Bhattacharya, None..
R. Kumar, None..
H. Singh, None..
J. K. Sahu, None..
N. Sankhyan, None.